Bioregnum channel feed – Endpoints News

Bioregnum channel feed

Michelle McMurry-Heath washed overboard at BIO as industry group wrestles over its future, hunts new CEO

3 years ago

It’s time we talked about biopharma — live in London next week

3 years ago

Jeff Marrazzo has found a buzzy new biotech cause to champion. And once again, he's all in

3 years ago

Join me in Boston today to meet biotech's top startups

3 years ago

ICYMI: James Sabry just signed off on a landmark first for Roche's dealmaking crew

3 years ago

Sometimes you win. Sometimes you lose. And sometimes it's just another PhIII canakinumab fail

3 years ago

Cerevel's Tony Coles is still counting his money as a rival's boost helps fuel a potential $609M windfall

3 years ago

George Yancopoulos says he's on the trail of the holy grail: ‘This could represent the next breakthrough for immunotherapy’

3 years ago

How do you put a positive spin on ugly data? AC Immune gives it a shot in the wake of the latest crenezumab flop

3 years ago

What can Merck afford to buy now? ‘ANYTHING’ it wants

3 years ago

The new CEO at Roche has followed a familiar path into the C-suite. But it's his next steps that are crucial to his success

3 years ago

Exclusive: Mark Pruzanski is once again reaching for the brass ring in biotech

3 years ago

BlackRock joins Andrew Lo's risk analysis firm to search for odds-on biotech bets in turbulent times

3 years ago

As the consumer group splits away today, what will New GSK buy now?

3 years ago

Faheem Hasnain forges a $120M private placement. So what did we learn from that?

3 years ago

No surrender: A group of marquee biotech players bets on the $350M PhIII resurrection story of a heavyweight contender

3 years ago

A portrait of a biotech buyout deal in savage times: turning a $15.50 offer into a $7.12 deal

3 years ago

Fresh report of 'advanced' $40B+ Seagen buyout talks spurs more buzz about FTC showdown

3 years ago

The 2022 Endpoints 11 is coming. Do you know a biotech that should be on the list?

3 years ago

Alzheimer's quick OK, take two: FDA offers Biogen, Eisai a shortcut to a possible lecanemab approval

3 years ago

Battle-tested biotech execs turn to an experienced industry godfather for some boardroom guidance

3 years ago

In lieu of hard M&A news, one group of analysts crunches the numbers around a $40B Seagen buy

3 years ago

#BIO22: Coming together at a critical time, Endpoints News looks at the key metrics on biopharma in a turbulent time

3 years ago

Moderna’s Cinderella story is getting a scary rewrite on Wall Street, and a top analyst points to one path to a happy ending

3 years ago

First page Previous page 1 2 345 6 7 Next page Last page